A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Hoffmann-La Roche
Hoffmann-La Roche
Fate Therapeutics
The Methodist Hospital Research Institute
Eli Lilly and Company
Masonic Cancer Center, University of Minnesota
UNC Lineberger Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
R-Pharm
Centre Jean Perrin
Merck KGaA, Darmstadt, Germany